Effect of DAAs on Behavior of HCC in HCV Patients

Personalized Cancer Vaccine in Egyptian Cancer Patients

NCT05059821 ·Status: UNKNOWN ·Phase: PHASE1

Epigenetic Changes in Hepatocellular Carcinoma Developed After Direct Acting Antiviral Therapy for Chronic Hepatitis C

NCT04220151 ·Status: UNKNOWN

A Phase 1-2 Study of CF102 in Patients With Advanced Hepatocellular Carcinoma

NCT00790218 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Direct Acting Antiviral-Post Authorization Safety Study

NCT03707080 ·Status: COMPLETED

Effectiveness and Safety of Lenvatinib Combined With Chinese Herbal Medicine for Patients With Unresectable Hepatocellular Carcinoma: A Real-world Study in China

NCT06315101 ·Status: COMPLETED

Study of ARQ 197 in Hepatocellular Carcinoma (HCC)

NCT01656265 ·Status: COMPLETED ·Phase: PHASE1

Clinical Study on the Efficacy of Acetazolamide Combined With Levamisole in the Treatment of HCC

NCT04611373 ·Status: UNKNOWN ·Phase: PHASE3

Sorafenib Versus Best Supportive Care in Egyptian Hepatocellular Carcinoma Patients.

NCT02971696 ·Status: COMPLETED ·Phase: PHASE3

The Effect of Viral Load on Intrahepatic Recurrence in Hepatitis B Virus (HBV)-Related Hepatocellular Carcinoma (HCC)

NCT00397540 ·Status: COMPLETED ·Phase: NA

COVID-19 Infection in Patients With Hepatocellular Carcinoma

NCT04367805 ·Status: ACTIVE_NOT_RECRUITING

Novel Treatment of Advanced Hepatocellular Carcinoma

NCT03950518 ·Status: UNKNOWN ·Phase: PHASE3

Use of Immune Checkpoint Inhibitors in Patients With Advanced Hepatocellular Carcinoma : Efficacy and Outcomes

NCT07321067 ·Status: NOT_YET_RECRUITING

The Utility of Cell-free DNA Methylation Markers for Hepatocellular Carcinoma

NCT05573217 ·Status: UNKNOWN

Evaluation of Efficacy and Safety of Immune Check Point Inhibitors in Hepatocellular Carcinoma Patients in Ain Shams University Hospitals

NCT07088081 ·Status: ENROLLING_BY_INVITATION

Comparison of HBV Reactivation Between Patients With High HBV-DNA and Low HBV-DNA Loads Undergoing ICI and Concurrent Antiviral Prophylaxis: a Prospective Observational Study

NCT04680598 ·Status: UNKNOWN

Anlotinib for Hepatocellular Carcinoma

NCT04954521 ·Status: UNKNOWN

"Cocktail" Therapy for Hepatitis B Related Hepatocellular Carcinoma

NCT04317248 ·Status: UNKNOWN ·Phase: PHASE2

Arabinoxylan Rice Bran (MGN-3/Biobran) for the Treatment of Hepatocellular Carcinoma and Hepatitis B and C Infection

NCT01018381 ·Status: COMPLETED ·Phase: NA

A Randomized Double-blind, Placebo-controlled Japanese Phase III Trial of ARQ 197 in Hepatocellular Carcinoma (HCC)

NCT02029157 ·Status: COMPLETED ·Phase: PHASE3

Residual Plasma Concentration of Sorafenib and Adverse Events in CHC

NCT03340636 ·Status: UNKNOWN

Pharmacogenetic of Doxorubicin in HCC.

NCT06313047 ·Status: COMPLETED

Lenvatinib Combined With TACE to Prevent the Recurrence in High-risk Patients With Hepatocellular Carcinoma

NCT03838796 ·Status: UNKNOWN ·Phase: NA

Durvalumab Plus Lenvatinib as First-line Treatment for Unresectable Hepatocellular Carcinoma

NCT05312216 ·Status: UNKNOWN ·Phase: PHASE2

Improving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C Virus Infection With Direct-Acting Antiviral Therapy

NCT05717400 ·Status: TERMINATED ·Phase: PHASE4

Study of Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With Unresectable Hepatocellular Carinoma

NCT05557838 ·Status: RECRUITING ·Phase: PHASE3